ANI Pharmaceuticals Inc (ANIP)

Debt-to-assets ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands 284,819 285,032 285,244 285,457 285,669 285,882 286,095 286,307 286,520 186,063 189,525 168,985 172,443 175,161 177,879 188,094 175,808 64,873 65,688 66,501
Total assets US$ in thousands 904,422 889,914 859,341 765,224 760,087 739,110 751,334 744,846 771,598 470,454 480,159 463,843 461,190 462,581 465,391 482,232 456,789 456,775 446,906 434,390
Debt-to-assets ratio 0.31 0.32 0.33 0.37 0.38 0.39 0.38 0.38 0.37 0.40 0.39 0.36 0.37 0.38 0.38 0.39 0.38 0.14 0.15 0.15

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $284,819K ÷ $904,422K
= 0.31

ANI Pharmaceuticals Inc's debt-to-assets ratio has been relatively stable over the past eight quarters, ranging from 0.32 to 0.39. This ratio indicates that between 32% to 39% of the company's total assets have been financed by debt during this period.

A decreasing trend in the debt-to-assets ratio from Q1 2023 to Q4 2022 may indicate that the company has been able to reduce its reliance on debt financing in relation to its total assets. However, the ratio increased in Q1 2023 compared to the previous quarter, which may suggest a recent increase in debt relative to assets.

Overall, the debt-to-assets ratio provides insight into the company's financial leverage and risk exposure. ANI Pharmaceuticals Inc's consistent range of debt-to-assets ratios indicates a relatively stable financial structure with a moderate level of debt financing compared to its total assets. However, it would be important to monitor any significant deviations from this range to assess potential changes in the company's capital structure and financial health.